LeMaitre (LMAT) Q1 2026 earnings review
Textbook Operating Leverage: Sales Up 11%, Profits Up 41%
LeMaitre delivered a masterclass in margin expansion this quarter. By pairing disciplined spending (+6% OPEX) with strong pricing power and manufacturing efficiencies (+350 bps gross margin), the company turned an 11% revenue increase into a 41% surge in operating income and a 42% spike in EPS. The international launch of Artegraft continues to exceed expectations, acting as a massive growth catalyst across EMEA and APAC. Management is highly confident, raising its full-year guidance and executing a $100M share repurchase authorization. This is a remarkably clean story of a niche medical device maker exercising its pricing power and expanding its global footprint without bloated cost structures.
🐂 Bull Case
Gross margins expanded by a massive 350 basis points to 72.7%. LeMaitre's dominance in niche vascular markets allows it to command significant ASP increases without sacrificing unit volumes.
Worldwide Artegraft sales surged 36% in Q1. The international launch (recently unlocked by the MDR CE mark) continues to be a major growth engine, especially in Europe.
🐻 Bear Case
While EMEA and APAC posted stellar growth (+20% and +18% respectively), the core Americas market decelerated to 7% YoY growth. If the US business stalls, international growth may not be enough to sustain the overall double-digit trajectory.
The company holds $367M in cash (58% of total assets). Without an immediate M&A target or aggressive execution of the new $100M buyback, this idle cash suppresses overall return on equity.
⚖️ Verdict: 🟢
Bullish. The company's "playbook"—niche products, direct sales channels, and aggressive pricing—is working flawlessly, translating low-double-digit top-line growth into massive bottom-line expansion.
Key Themes
Relentless Margin Expansion
The fundamental driver of LeMaitre's story is its widening margins. Gross margin jumped from 69.2% a year ago to 72.7%. Operating margin reached 27%, up from 21% in 25Q1. Management attributed this to higher average selling prices (ASPs), manufacturing efficiencies, and highly disciplined operating expense growth (up only 6% YoY).
International Direct Sales Strategy Paying Off
The transition from distributors to direct sales in international markets is generating outsized returns. EMEA sales posted record numbers, accelerating to 20% YoY growth ($20.3M). APAC, which saw "softness" specifically in Japan last year, reversed trend and grew an impressive 18% YoY ($4.7M). Artegraft is the primary beneficiary of this expanded European direct footprint.
Americas Segment Decelerating
While total company metrics look spectacular, the Americas region—representing 63% of total revenue—is showing signs of fatigue. It grew just 7% YoY ($41.6M) in 26Q1, down from 10% in 25Q4 and 10% in 25Q3. Given that management pushes aggressive US price hikes (8%+ annually), single-digit revenue growth implies slightly negative or flat unit volumes domestically.
Broad-Based Product Strength
The product portfolio is firing on all cylinders. Beyond the standout 36% growth in Artegraft, core legacy products delivered robust numbers: Grafts (+20%), Valvulotomes (+15%), and Carotid Shunts (+11%). The sustained growth in Carotid Shunts indicates that the long-term headwinds feared from the CREST-2 trial (favoring stenting) have not yet materialized, and LeMaitre maintains its near-monopoly position.
Capital Allocation Paradox
LeMaitre is a cash-generating machine, adding $8.1M sequentially to reach a staggering $367.2M in cash and short-term investments. However, M&A remains elusive, and previous quarters indicated zero execution on share repurchases. A newly authorized $100M buyback program provides an avenue for capital return, but investors should monitor whether management actually pulls the trigger or continues hoarding cash.
Manufacturing Facility Consolidation Risk
In prior quarters, management flagged that consolidating the RestoreFlow facility from Chicago to Burlington would be a "slight headwind" to gross margins in 2026. While Q1 margins were exceptional at 72.7%, guidance implies a slight step-down to 72.1% in Q2, likely reflecting the onset of these dual-facility running costs.
Other KPIs
Up $8.1 million sequentially from year-end 2025. This fortress balance sheet fully covers the company's $168.8 million in convertible debt and provides massive dry powder for the $100 million buyback authorization or potential acquisitions in the $15M-$150M revenue sweet spot.
Grew only 6% YoY. This is a dramatic deceleration from the 16% to 20% OPEX growth seen in early 2025 when the company was aggressively expanding its direct sales force. The current restraint proves that the sales reps hired last year are now highly productive, allowing revenues to outpace costs significantly.
Guidance
Stable. The midpoint of $71.5M implies 11% YoY growth (11% organic), exactly matching the growth rate achieved in 26Q1. This indicates strong, consistent momentum without any expected demand drop-offs.
Decelerating slightly. The midpoint of $0.81 implies 35% YoY growth. While slower than Q1's 42% surge, it still represents phenomenal operating leverage and significantly outpaces the 11% top-line growth.
Stable. Midpoint of $280M represents 12% YoY growth (12% organic). This confirms that management views the current low-double-digit growth trajectory as sustainable for the entire year, likely backed by previously announced 8% price increases.
Decelerating. The midpoint of $3.00 implies a 26% adjusted YoY growth rate. While operating margins are expected to average 29% for the year, potential headwinds from the Chicago facility consolidation and typical Q3 seasonality moderate the back-half growth rates compared to the explosive Q1.
Key Questions
Americas Growth Deceleration
The Americas segment grew only 7% this quarter despite an 8% list price increase taking effect in January. Are domestic unit volumes shrinking, and what is the strategy to re-accelerate the core US business?
Execution of Capital Returns
With $367M in cash and a newly authorized $100M share repurchase program, what is the timeline and pacing for these buybacks? Does this aggressive buyback signal a pause in the pursuit of M&A?
Gross Margin Trajectory
Gross margin hit an impressive 72.7% in Q1 but is guided down to 72.1% in Q2. Is this entirely due to the anticipated RestoreFlow facility transfer from Chicago to Burlington, and when do you expect those overlapping costs to clear?
Update on China Business
Last year, the China segment was facing headwinds and the cardiac patch launch was struggling. Has the APAC rebound (+18% YoY) been driven by a recovery in China, or is it isolated to other regions?